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AbstrAct
Objective Bone health in SLE is adversely affected 
by vitamin D deficiency, inflammatory cytokines and 
glucocorticoid use. We hypothesised that vitamin D 
supplementation would increase markers of bone 
formation and decrease markers of bone resorption in SLE 
subjects.
Methods We studied 43 vitamin D-deficient SLE subjects 
who participated in a 12-week randomised controlled 
trial of 2000–4000 IU/day vitamin D supplementation 
versus placebo. Subjects had inactive SLE (SLE Disease 
Activity Index ≤4) and were taking <20 mg prednisone 
daily at baseline. We assayed baseline and week 12 serum 
25-hydroxyvitamin D, N-terminal propeptide of type 1 
collagen (P1NP) and C-telopeptide (CTX). We tested the 
effect of vitamin D versus placebo on change (Δ) in P1NP 
and ΔCTX in an intention-to-treat analysis. Secondary 
analyses evaluated whether vitamin D affected bone 
turnover among subjects achieving vitamin D repletion 
(≥30 ng/mL) or currently taking glucocorticoids.
Results 28 subjects were randomised to vitamin D 
and 15 to placebo. Mean age was 39 years and 40% 
were using glucocorticoids at enrolment. Repletion was 
achieved by 46% in the vitamin D group versus none in the 
placebo group. Changes in bone turnover markers were 
not significantly different in the vitamin D group versus 
placebo group (median ΔP1NP −0.2 vitamin D group vs 
−1.1 placebo group (p=0.83); median ΔCTX +3.5 vitamin 
D group vs −37.0 placebo group (p=0.50)). The effect 
of vitamin D did not differ based on achieving vitamin D 
repletion or baseline glucocorticoid use.
Conclusion Vitamin D supplementation did not affect the 
12-week change in bone turnover markers among SLE 
subjects in this trial.
IntROduCtIOn
Poor bone health is common in SLE due to 
disease and treatment. Patients with SLE have 
twice the fracture risk of individuals without 
SLE, and patients with SLE with nephritis 
are at even greater risk.1–3 Systemic inflam-
mation, glucocorticoid use, lupus nephritis, 
premature menopause and vitamin D defi-
ciency all have deleterious effects on bone 
health. Numerous studies have demonstrated 
that lower vitamin D levels are associated with 
higher SLE disease activity, although trials of 
vitamin D supplementation for reducing SLE 
disease activity have had conflicting results.4–7 
Data on vitamin D supplementation for 
bone health in SLE are mostly derived from 
observational studies, raising concerns about 
confounding by indication; patients with SLE 
perceived to be at highest risk for fracture 
may be more likely to receive vitamin D.
Circulating vitamin D affects bone metab-
olism through direct effects on bone and by 
influencing intestinal calcium absorption and 
parathyroid hormone (PTH) levels.8 Bone 
resorption by osteoclasts and bone forma-
tion by osteoblasts are coupled, such that an 
increase in bone resorption is followed by an 
increase in bone formation. The dynamic 
processes of bone resorption and formation 
can be measured using biomarkers of bone 
turnover. The International Osteoporosis 
Foundation recommends using N-terminal 
propeptide of type 1 collagen (P1NP) as a 
marker of bone formation and C-telopep-
tide (CTX) as a marker of bone resorption 
in clinical research.9 In the setting of vitamin 
D deficiency, calcium absorption decreases 
and PTH level increases, leading to increased 
bone resorption paired with increased bone 
formation. Vitamin D repletion is expected 
to increase calcium absorption and decrease 
PTH level, thereby decreasing both bone 
resorption (eg, decreasing the level of CTX) 
and formation (eg, decreasing the level of 
P1NP).
Limited data from cross-sectional studies 
in SLE suggests that higher vitamin D levels10 
and lower SLE disease activity10 are associated 
with higher levels of bone formation markers. 
Due to their observational nature, past studies 
that focused on vitamin D deficiency in SLE 
have been unable to test whether vitamin D 
repletion decreases bone turnover.
We investigated the effect of vitamin D 
supplementation on changes in bone turnover 
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markers in a randomised controlled trial in vitamin D-de-
ficient patients with SLE. We hypothesised that vitamin 
D supplementation would lead to a greater decrease in 
P1NP and CTX levels compared with placebo.
MethOds
study population
Subjects had completed a randomised, double-blinded, 
placebo-controlled trial testing the effect of vitamin D3 
supplementation on expression of genes induced by 
interferon-alpha (‘interferon gene signature’) in patients 
with SLE (NCT00710021).6 The primary outcome was 
a reduction in the interferon gene signature at week 
12. Fifty-seven SLE subjects were randomised at six US 
sites from 2009 to 2011; 54 subjects were included in a 
modified intention-to-treat analysis (three subjects never 
received a dose of study drug). Stored blood samples 
were available for the current study for 43 subjects (28 
in vitamin D intervention arms and 15 in placebo arm).
enrolment criteria
Female and male patients aged ≥18 years who fulfilled 
American College of Rheumatology 1997 classification 
criteria for SLE were recruited. Vitamin D deficiency 
(serum 25-hydroxyvitamin D (25(OH)D) ≤20 ng/mL) 
was required. Stable, inactive SLE (Safety of Estro-
gens in Lupus Erythematosus National Assessment 
(SELENA)-SLE Disease Activity Index (SLEDAI) ≤4),11 
prednisone <20 mg/day or no prednisone and a stable 
immunosuppressant regimen were required. Exclusion 
criteria are listed in the online supplementary 1.
treatment groups
Subjects were randomised 1:1:1 to vitamin D 2000 IU/
day, 4000 IU/day or placebo. Due to limited sample 
size, subjects randomised to vitamin D 2000 IU/day or 
4000 IU/day were analysed together to maximise statis-
tical efficiency. Treatment adherence was assessed at 
week 12: vitamin D repletion (serum 25(OH)D ≥30 ng/
mL) was considered evidence of adherence to vitamin D 
or non-adherence to placebo.
study visits and data collection
Eligibility was confirmed at a screening visit including 
a blood draw, medical history, medication review and 
physical examination. Study visits at baseline and week 
12 included a blood draw, medical history, medication 
review, questions about symptoms and physical examina-
tion. SLE disease activity was measured at each visit using 
the SELENA-SLEDAI, modified to include spot urine 
protein/creatinine ratio. Rho, Inc. managed data collec-
tion and quality control.
Laboratory evaluation
Serum 25(OH)D was measured in baseline and week 
12 samples centrally at the Medical University of South 
Carolina (Hollis laboratory) using a radioimmunoassay 
(DiaSorin, Stillwater, Minnesota, USA).12
Expression of three genes induced by interferon-alpha 
(Mx1, Ifit1 and Ifi44) at baseline and week 12 was deter-
mined using reverse transcription-PCR (TaqMan assay) 
performed at Feinstein Institute for Medical Research 
(Diamond laboratory) on whole blood collected using 
Pax gene tubes. Interferon gene signature was computed 
relative to expression of these genes in healthy controls.6
Bone turnover markers, P1NP and CTX, were measured 
at the Brigham and Women’s Hospital Research Assay 
Core using excess baseline and week 12 blood samples 
that had been stored at −80°C at Feinstein Institute for 
Medical Research (Biorepository). P1NP and CTX were 
measured in serum with one exception noted in online 
supplementary file 2. P1NP was measured by radioimmu-
noassay (Orion Diagnostics, Finland) with intra-assay coef-
ficient of variation (CV) 3.2%–7.1%. CTX was measured 
by immunoradiometric assay (Serum CrossLaps, Arizona, 
USA) with intra-assay CV 1.8%–5.0%. See online supple-
mentary 2 for further details.
statistical analysis
Changes (Δ) in 25(OH)D, P1NP and CTX were calcu-
lated as week 12 minus baseline value. We estimated 
correlations between baseline 25(OH)D and bone turn-
over markers, and correlations between Δ25(OH)D and 
changes in bone turnover markers, ΔP1NP and ΔCTX, 
using Spearman coefficients. Change in 25(OH)D, P1NP 
and CTX within each study arm was evaluated using 
signed rank tests. We tested the effect of vitamin D supple-
mentation versus placebo on ΔP1NP and ΔCTX using 
Wilcoxon rank-sum tests in an intention-to-treat analysis. 
We performed several sensitivity analyses testing (1) if 
ΔP1NP and ΔCTX differed across the three original study 
arms, (2) whether achieving vitamin D repletion versus 
not affected changes in bone turnover markers and (3) 
the effect of vitamin D in subgroups by baseline gluco-
corticoid use (any/none) and baseline interferon-alpha 
gene signature (detectable/undetectable). The final 
sensitivity analysis excluded subjects taking bisphospho-
nates at baseline.
Analyses were performed using SAS V.9.4. A two-tailed 
p value <0.05 was considered statistically significant.
ResuLts
We analysed results from 43 subjects: 28 randomised to 
vitamin D (2000 or 4000 IU/day) and 15 randomised to 
placebo (see online supplementary 3). Black race, the 
presence of a detectable interferon gene signature and 
glucocorticoid use were more common among subjects 
randomised to vitamin D (table 1).
Among all subjects, baseline 25(OH)D was inversely 
correlated with baseline P1NP (r=−0.31, p=0.04) but not 
with baseline CTX (r=−0.07, p=0.68). Twelve-week change 
in 25(OH)D was not significantly correlated with ΔP1NP 
(r=0.003, p=0.99) or ΔCTX (r=0.07, p=0.64).
Vitamin D significantly increased among subjects in the 
vitamin D group; subjects in the placebo group also had 
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Table 1 Baseline characteristics of SLE subjects in a 
randomised trial of vitamin D versus placebo
Vitamin D* (n=28) Placebo (n=15)
Demographics
  Age, years 34.5 (29.5–45.0) 37.0 (30.0–50.0)
  Female 92.9 93.3
  Race
   White 32.1 60.0
   Black 53.6 40.0
   Other 14.3 0
SLE characteristics
  Disease duration, years 8.0 (3.9–14.2) 10.0 (3.3–16.0)
  ANA positive 96.4 86.7
  Anti-double stranded DNA 
positive
92.9 93.3
  Renal disorder 35.7 40.0
  SELENA-SLEDAI score 3 (2–4) 4 (2–4)
  Interferon gene signature 
detectable
89.3 73.3
Laboratory values
  CTX, mg/L 80.0 (34.0–118.5) 76.0 (64.0–147.0)
  P1NP, μg/L 45.2 (31.8–62.2) 48.9 (31.5–74.3)
  Serum 25-hydroxyvitamin D, 
ng/mL
11.9 (10.1–14.4) 9.9 (6.9–14.5)
Medications
  Glucocorticoids, prednisone equivalent
   0 mg/day 57.1 66.7
   >0 to <7.5 mg/day 25.0 20.0
   ≥7.5 mg/day 17.9 13.3
  Antimalarial 60.7 80.0
  Azathioprine 25.0 6.7
  Methotrexate 14.3 0
  Mycophenolate 32.1 33.3
  Bisphosphonate 10.7 6.7
Presented as median (IQR) or %.
*2000 IU daily (low dose) or 4000 IU daily (high dose).
CTX, C-telopeptide; P1NP, N-terminal propeptide of type 1 collagen; SELENA-SLEDAI, 
Safety of Estrogens in Lupus National Assessment-SLE Disease Activity Index.
Figure 1 Within-group and between-group change in (A) 
25-hydroxyvitamin D (25(OH)D), (B) N-terminal propeptide 
of type 1 collagen (P1NP) and (C) C-telopeptide (CTX) from 
baseline to week 12.
a significant but smaller increase in vitamin D (figure 1A). 
The median increase in 25(OH)D was significantly greater 
among subjects in the vitamin D group (16.9 (IQR 13.8–
21.0) ng/mL) than placebo (4.4 (IQR −1.3 to 6.6) ng/
mL) (p<0.01). Median P1NP did not significantly change 
between baseline and week 12 in the vitamin D or placebo 
group, and the between-group difference was not significant 
(figure 1B). Likewise, median CTX was not significantly 
different at baseline and week 12 in either group, and the 
between-group difference was not significant (figure 1C). 
The online supplementary 4 presents individual-level data.
Changes in bone turnover markers were similar in the 
three original study arms (table 2). Changes in P1NP and 
CTX were similar among 13 subjects who achieved versus 
30 who did not achieve vitamin D repletion. In anal-
yses stratified by baseline glucocorticoid use, we did not 
observe a difference in ΔP1NP or ΔCTX in the vitamin D 
versus placebo group. Changes in bone turnover markers 
did not differ by vitamin D versus placebo group among 
subjects with or without a detectable interferon signa-
ture at baseline. Results were similar after excluding four 
subjects using bisphosphonates at baseline.
dIsCussIOn
In this randomised, placebo-controlled trial in vitamin 
D-deficient SLE subjects, we observed small changes in 
P1NP and CTX at 12 weeks in the vitamin D and placebo 
groups. Baseline serum 25(OH)D was inversely associated 
with baseline P1NP, but change in 25(OH)D at 12 weeks 
was not correlated with change in bone turnover markers. 
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Table 2 Sensitivity analyses
Change in P1NP, μg/L P value Change in CTX, mg/L P value
Original study arms
  4000 IU/day (n=16) 1.5 (−13.8 to 4.4) 0.93 9.0 (−43.5 to 74.0) 0.33
  2000 IU/day (n=12) −0.4 (−2.9 to 6.7) −8.5 (−45.5 to 8.0)
  Placebo (n=15) −1.1 (−6.8 to 13.0) −37.0 (−74.0 to 34.0)
Vitamin D repletion achieved
  Yes (n=13) 1.5 (−0.5 to 5.3) 0.40 −3.0 (−48.0 to 10.0) 0.74
  No (n=30) −1.2 (−8.3 to 8.4) −2.5 (−52.0 to 34.0)
Using glucocorticoids at baseline
  Vitamin D (n=12) −0.4 (−5.1 to 7.1) 0.96 8.0 (−35.0 to 15.5) 0.33
  Placebo (n=5) −1.2 (−6.8 to 3.8) −37.0 (−52.0 to −11.0)
Not using glucocorticoids at baseline
  Vitamin D (n=16) 0.6 (−8.6 to 3.8) 0.73 −1.0 (−58.5 to 43.5) 0.90
  Placebo (n=10) 0.3 (−4.9 to 13.0) −10.0 (−74.0 to 46.0)
Interferon signature detectable at baseline
  Vitamin D (n=25) −0.5 (−8.3 to 2.2) 0.52 1.0 (−48.0 to 14.0) 0.22
  Placebo (n=11) −1.2 (−6.8 to 13.2) −40.0 (−84.0 to 34.0)
Interferon signature undetectable at baseline
  Vitamin D (n=3) 15.8 (10.8 to 16.1) 0.16 31.0 (−39.0 to 364.0) 0.87
  Placebo (n=4) 0.3 (−5.0 to 7.4) 22.0 (−27.0 to 493.5)
Subjects not using bisphosphonates at baseline
  Vitamin D (n=25) −0.2 (−4.0 to 4.1) 0.63 6.0 (−39.0 to 17.0) 0.51
  Placebo (n=14) 0.3 (−4.9 to 13.0) −38.5 (−74.0 to 34.0)
P values from Kruskal-Wallis test for three-group comparison and Wilcoxon rank-sum test for two-group comparisons.
Changes in P1NP and CTX were similar in the vitamin 
D and placebo groups in analyses stratified by vitamin D 
repletion, baseline glucocorticoid use and baseline inter-
feron-alpha gene signature.
Bone turnover markers are useful endpoints for clinical 
research studies because they change more rapidly than 
bone mineral density in response to bone-active thera-
pies.13 They generally increase or decrease together due 
to the homeostatic relationship between bone formation 
and resorption. Glucocorticoid use disrupts this homeo-
stasis, leading to predominantly decreased bone forma-
tion and possibly increased bone resorption.14 Therefore, 
it is possible that the effect of vitamin D on bone turn-
over markers differs in patients using versus not using 
glucocorticoids. We did not observe a differential effect 
of vitamin D versus placebo based on glucocorticoid use, 
though the small sample size limited our ability to draw 
definitive conclusions. See online supplementary 5 for 
further context.
Our study had several strengths, including a 
randomised, double-blind, placebo-controlled design 
among patients with SLE with similar renal function 
(serum creatinine ≤1.5 mg/dL), pertinent to P1NP and 
CTX assays. All subjects were aged <50 years, corre-
sponding with premenopausal years among female 
subjects. We measured P1NP and CTX, the bone turnover 
markers recommended by the International Osteoporosis 
Foundation for use in clinical trials.
Our study had important limitations, including the 
short duration and limited sample size. As the study 
population was small, the study lacked statistical power 
for definitive conclusions. Not all subjects consented to 
secondary use of their blood samples and banked blood 
sample quantity was insufficient for some; thus, serum 
biomarkers from 11 trial participants were not assayed. 
Subjects were recruited across all seasons so seasonal 
variation in endogenous vitamin D synthesis might have 
affected the results, particularly the increase in vitamin D 
in the placebo group. Both female and male SLE subjects 
were included; sex-based differences in bone metabolism 
may have impacted our results. Participants had stable, 
inactive SLE and our results may not generalise to patients 
with high SLE disease activity.
We did not observe a significant decrease in bone 
turnover markers in the vitamin D group compared with 
placebo overall or in the small subgroup using gluco-
corticoids at baseline. However, this subgroup analysis 
(and likely the overall analysis) was underpowered due 
to small sample size, allowing the possibility that an effect 
of vitamin D on bone turnover markers was not observed 
even if a true effect exists. We advise that patients with 
SLE and their clinicians continue to follow the American 
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College of Rheumatology’s Glucocorticoid-Induced Oste-
oporosis guidelines, which include optimising vitamin D 
intake, as the current study was not designed to investi-
gate bone density or fracture outcomes.15 16 A larger, 
longer-term trial of vitamin D versus placebo in patients 
with SLE—particularly premenopausal women with high 
disease activity—using bone mineral density or bone 
microarchitecture as outcomes would help guide clinical 
care.
COnCLusIOns
In this small randomised trial in vitamin D-deficient 
patients with SLE, we did not observe a change in P1NP 
or CTX at 12 weeks in subjects randomised to vitamin 
D 2000–4000 IU/day versus placebo. Larger trials in 
premenopausal, vitamin D-deficient patients with SLE 
focused on changes in bone mineral density or bone 
microarchitecture could elucidate the effect of vitamin D 
supplementation in this population with increased frac-
ture risks.
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